

Rapid Test for Detection of Antibodies to HIV 1 & HIV 2 - Device/Cassette (From Human Serum / Plasma / Whole Blood)

For *In-Vitro* Diagnostic Use Only

Store at 4°C to 30°C

INTENDED USE

"Rapid test for detection of Antibodies to HIV 1 and HIV 2- Device/Cassette" is an immunoassay for the rapid and visual detection of Antibodies to HIV 1 and HIV 2 in human serum/plasma/whole blood for the diagnosis of Human Immunodeficiency Virus infection (HIV).

PRINCIPLE

After addition of the serum/plasma/whole blood sample and assay buffer to the sample well of the device containing a test strip, the sample moves on to the conjugate pad containing colloidal gold particles conjugated with recombinant HIV 1, HIV 2 antigen and Mouse IgG Antibody. If the sample contains detectable levels of the Antibodies against HIV 1/HIV 2 or both Antigens, it reacts with the gold conjugated respective Antigen to form a complex. This complex moves further and reacts with HIV 1/HIV 2 Antigen coated as a separate test lines on the nitrocellulose membrane to form colored band at respective region. The unbound complex and the Mouse IgG conjugated colloidal gold particles move further to the goat anti-Mouse IgG coated control area to form a colored band (Control line). The appearance of test line/s and control line in respective area indicates the positive result. Appearance of only control line indicates a negative result. The control line acts as a procedural control. Control line should always appear if the test is performed as per the procedure and reagents are working properly.

CONTENTS OF KIT

1. Pouches of Test device With Desiccant
2. Assay Buffer Bottle
3. Plastic Dropper
4. Package Insert

OPTIONAL MATERIAL REQUIRED

1. Stop Watch
2. Sample Container
3. Disposable gloves

PRECAUTIONS/KIT STORAGE AND STABILITY

1. Please read all information in the pack insert carefully before performing the test. Pay particular attention to the position of the Control and Test lines.
2. Do not use expired test, Expiry date is printed on the foil pouch and kit.
3. Store kit in a dry place at temperature 4°C to 30°C. Do not freeze.
4. Do not use if pouch is torn or damaged.
5. Do not open the foil pouch until you are ready to start the test.
6. Keep out of reach of children.

WARNINGS

1. Do not reuse the test.
2. Follow the instruction to get accurate results.
3. Use appropriate personal protective equipments.
4. Dispose off hygienically in Biohazard waste.
5. Do not touch the membrane.
6. Treat used samples and tests as potentially infectious. Avoid contact with skin.
7. For in vitro diagnostic use. Not to be taken internally.
8. Do not eat the desiccant in the package.
9. Do not mix the different specimen samples or interchange the different specimen.
10. The manufacturer and distributor of this product shall not be liable for any losses, liability, claims, costs or damages whether direct or consequential arising out of or related to an incorrect diagnosis, whether positive or negative, in the use of this product.

SPECIMEN COLLECTION

1. This test can be performed using serum/plasma/whole blood.
2. Testing should be performed immediately after the Collection of samples. Do not leave the specimen at room temperature for prolonged periods.
3. For whole blood, Fresh anti coagulated whole blood should be used as a test sample. EDTA or Heparin or Oxalate or Tri-sodium Citrate can be used as suitable anticoagulants.
4. The specimen should be collected in a clean glass or plastic container. If immediate testing is not possible then store the specimen at 2°C to 8°C for up to maximum three days.
5. Do not use hemolyzed, turbid or contaminated samples. Turbid samples should be centrifuged and only clear supernatant must be used for testing.

TEST PROCEDURE

1. Allow the kit components and sample to reach room temperature (20°C to 30°C).
2. Tighten the vial cap of the assay buffer provided with the kit in the clockwise direction to pierce the dropper bottle nozzle.
3. Remove the test device, plastic dropper and desiccant pouch from the pouch. Check the color of desiccant it should be blue, if it has turned colorless or pink, discard the test and use another test.
4. Label the test with patient's identity
5. Place the device on flat plane surface & add 1 drop (Approx. 30 µl) of serum/plasma or 2 drops of whole blood (Approx. 60 µl) sample in well "S".

6. Immediately dispense one drop (Approx. 30 µl) of assay buffer into well "S", by holding the plastic dropper bottle vertically.

7. Start the timer.

8. Read the result at 15 minutes. Do not read the result after 20 minutes.

INTERPRETATION OF RESULTS

Negative: If colored line appears at the control region 'C' only.



HIV 1 Positive: A distinct colored line appears at the control region 'C' and at the test region '1'.



HIV 2 Positive: A distinct colored line appears at the control region 'C' and at the test region '2'.




HIV 1 and 2 Positive: A distinct colored lines appears at the control region 'C' and at the test regions '1' and '2'.




Invalid: The test should be considered invalid if,
A) No line appears at 'C', '1' and '2' regions



B) No line appears at 'C' and '2' region and line appears only at '1' region



C) No line appears at 'C' and '1' region and line appears only at '2' region



D) No line appears at 'C' region and line appears at '1' and '2' regions



NOTE: The intensity of color in the test lines region (1 & 2) will vary depending on the levels of the antibody in the specimen. However, neither the quantitative value nor the rate of increase in level of antibody in the specimen can be determined by this qualitative test. Positive results may appear as early as five minutes. Negative results must be confirmed only at the end of 15 minutes.

PERFORMANCE CHARACTERISTICS

Internal Evaluation:

In an in-house study, total 248 samples were evaluated for sensitivity and specificity. We found the relative sensitivity was 100 % (i. e. 48/48) and the relative specificity was 100 % (i. e. 200/200).

The results are summarized in the following table:

Sample	Total Number of Samples Tested	ImmunoQuick HIV 1/2 Ab Test Device		Sensitivity (%)	Specificity (%)
		Positive	Negative		
HIV 1 Positive Serum Samples	25	25	0	100	-
HIV 2 Positive Serum Samples	03	03	0	100	-
HIV 1 Positive Plasma Samples	10	10	0	100	-
HIV 1 Positive Blood Samples	10	10	0	100	-
Negative Human Serum Samples	150	0	150	-	100
Negative Human Plasma Samples	25	0	25	-	100
Negative Whole Blood Samples	25	0	25	-	100

Cross reactivity was studied with HBsAg, HCV, Syphilis positive samples. No cross reactivity was observed.
External Evaluation:
ImmunoQuick HIV 1 / 2 Ab test device were evaluated at NIB (National Institute of Biologicals) Ministry of Health and Family welfare, Government of India. Sensitivity was found 100 % and the specificity was found 100 %.

LIMITATIONS

This test provides presumptive diagnosis of HIV. A confirmed HIV diagnosis should only be made by a physician after all clinical and laboratory findings have been evaluated.


DISCLAIMER

The all precaution shall be taken to ensure the diagnostic ability and accuracy of this product. This product is utilized outside the control of manufacturer and distributors. The various factors including storage temperature, environmental conditions and procedure error may affect the results. Hence, positive test needs to be confirmed by confirmatory tests.

REFERENCES

1. Guyader, M., Emerman, M., Sonigo, P., et al. Genome organization and transactivation of the human immunodeficiency virus type 2. Nature 326:662-669, 1987.
2. Blattner, W., Gallo, R.C., and Temin, H.M. HIV causes AIDS. Science 241:515, 1988.
3. Curran, J.W., Morgan, W.M., Hardy, A.M., et al. The epidemiology of AIDS; Current status and future prospects. Science 229:1352-1357, 1985
4. Sarngadharan, M.G., Popovic, M., Bruch, L., Schüpbach, J., and Gallo, R.C. Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. Science 224:506-508,1984
5. Gallo, R.C., Salahuddin, S.Z., Popovic, M., et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224:500-503, 1984
6. Weber, J.N., Weiss, R.A., Roberts, C., et al. Human immunodeficiency virus in two cohorts of homosexual men; Neutralising sera and association of anti-gag antibody with prognosis. Lancet 1:119-124, 1987
7. Clavel, F., Gu(tard, D., Brun-V(zinet, F., et al. Isolation of a new human retrovirus from West African patient with AIDS
8. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired Immunodeficiency syndrome. MMWR 36 (suppl. no. 1S):1S-15S, 1987
9. World Health Organization/Global Programme on AIDS. Report of a WHO workshop on synthetic peptides in HIV diagnosis and AIDS-related research, Moscow 24-26 May 1989. WHO Report, AIDS 1991, 5: WHO1-WHO9

9. Los Alamos National Laboratory. Human retroviruses and AIDS Database. A compilation of nucleic acid and amino acid sequences, 1993.
10. World Health Organization/Global Programme on AIDS. Operational characteristics of commercially available assays to detect antibodies to HIV-1 and/or HIV-2 in human sera. Geneva, Switzerland: WHO documents GPA/BMR/89.4; GPA/BMR/90.1; GPA/RES/DIA90.1; GPA/RES/DIA/91.6;

	In Vitro Diagnostic Use
	Manufacturer
	Manufacturing Date
	Expiry Date
	Lot Number
	Store at 4°C to 30°C
	Single Use
	Number of tests in the pack
	Do not use if pouch or kit damaged
	This side Up
	Read package insert before use



MANUFACTURED BY
ImmunoScience India Private Limited
Gat No. 41, Kusgaon, Shivapur-Velhe Road,
Tal- Bhor, Pune, Maharashtra (India) -412205.